

Erratum to: Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis

Norio Komatsu¹ · Keita Kirito² · Kazuya Shimoda³ · Takayuki Ishikawa⁴ · Kohshi Ohishi⁵ · Kazuma Ohyashiki⁶ · Naoto Takahashi⁷ · Hikaru Okada⁸ · Taro Amagasaki⁸ · Toshio Yonezu⁸ · Koichi Akashi⁹

Published online: 7 February 2017
© The Japanese Society of Hematology 2017

Erratum to: Int J Hematol
DOI 10.1007/s12185-016-2130-z

The author would like to correct the error in the publication of the original article. The corrected detail is given below for your reading:

The first sentence in the “Results” section under the heading “Patients” should read as “A total of 51 patients were enrolled in this study from April 2014 to September 2014.”

The online version of the original article can be found under doi: [10.1007/s12185-016-2130-z](https://doi.org/10.1007/s12185-016-2130-z).

✉ Norio Komatsu
komatsun@juntendo.ac.jp

¹ Department of Hematology, Juntendo University School of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan

² Department of Hematology and Oncology, University of Yamanashi, Yamanashi 409-3898, Japan

³ Department of Gastroenterology and Hematology, University of Miyazaki, Miyazaki 889-1692, Japan

⁴ Department of Hematology, Kobe City Medical Center General Hospital, Kobe 650-0047, Japan

⁵ Blood Transfusion Service, Mie University, Tsu, Mie 514-8507, Japan

⁶ Department of Hematology, Tokyo Medical University, Tokyo 160-8402, Japan

⁷ Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita 010-8502, Japan

⁸ Novartis Pharma KK, Tokyo 105-6333, Japan

⁹ Department of Medicine and Biosystemic Science, Kyushu University, Fukuoka 812-8582, Japan